Chilton FH
Brightmeds offers some of these combination formulations, though availability may vary
The popularity of GLP-1 agonists to treat obesity has been skyrocketing in recent months, leading to both shortages and price increases
A 2026 review in Clinical Obesity covering 480,825 GLP-1 patients found elevated rates of B12, iron, zinc, and vitamin D deficiency, driven primarily by reduced total food intake
JMH has received honoraria and/or travel grants from Ablynx, Alexion, AstraZeneca Rare Disease, AstraZeneca, Bayer, Bouchara-Recordati, Fresenius, GlaxoSmithKline, Mundipharma, Merck Sharp & Dohme, Roche, Servier, Sanofi, and Vifor Fresenius
Patients should never interchange Ozempic and Wegovy or adjust doses without explicit guidance from their healthcare provider, as the formulations and approved indications differ